Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:NUVA

NuVasive (NUVA) Stock Price, News & Analysis

NuVasive logo

About NuVasive Stock (NASDAQ:NUVA)

Advanced Chart

Key Stats

Today's Range
$39.75
$39.75
50-Day Range
$38.12
$40.66
52-Week Range
$35.17
$49.53
Volume
N/A
Average Volume
1.16 million shs
Market Capitalization
$2.08 billion
P/E Ratio
79.50
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive NUVA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for NuVasive and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

NUVA Stock News Headlines

The End of Elon Musk…?
The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, and he's been proven right time and time again. And now, while the media focuses on Tesla's "demise," he's uncovered an AI breakthrough that's about to make Elon's doubters eat their words yet again. According to his research, if you listen to the media and miss out on Elon's newest breakthrough, it's going to cost you the fortune of a lifetime.tc pixel
Globus Medical: Some Caution After Its Deal For Nevro
Globus acquisition of Nevro complicates story, says Stifel
See More Headlines

NUVA Stock Analysis - Frequently Asked Questions

NuVasive, Inc. (NASDAQ:NUVA) announced its quarterly earnings results on Wednesday, August, 2nd. The medical device company reported $0.56 EPS for the quarter, hitting analysts' consensus estimates of $0.56. The company's revenue for the quarter was up 2.4% compared to the same quarter last year.
Read the conference call transcript
.

NuVasive subsidiaries include Simplify Medical, SafePassage, Vertera Spine, Biotronic NeuroNetwork, Ellipse Technologies, NuVasive Clinical Services Monitoring Inc., NuVasive Japan KK, NuVasive Specialized Orthopedics Inc., and NuVasive Technology International Limited.

Based on aggregate information from My MarketBeat watchlists, some other companies that NuVasive investors own include Meta Platforms (META), Tesla (TSLA), NVIDIA (NVDA), First Solar (FSLR), Netflix (NFLX), Advanced Micro Devices (AMD) and Home Depot (HD).

Company Calendar

Last Earnings
8/02/2023
Today
8/30/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Medical Devices
Sub-Industry
Health Care Equipment
Current Symbol
NASDAQ:NUVA
CIK
1142596
Employees
3,000
Year Founded
1997

Profitability

EPS (Trailing Twelve Months)
$0.50
Trailing P/E Ratio
79.50
Forward P/E Ratio
17.91
P/E Growth
N/A
Net Income
$40.41 million
Net Margins
2.32%
Pretax Margin
3.41%
Return on Equity
12.17%
Return on Assets
4.88%

Debt

Debt-to-Equity Ratio
0.50
Current Ratio
1.25
Quick Ratio
0.65

Sales & Book Value

Annual Sales
$1.23 billion
Price / Sales
1.70
Cash Flow
$4.96 per share
Price / Cash Flow
8.01
Book Value
$17.02 per share
Price / Book
2.34

Miscellaneous

Outstanding Shares
52,449,000
Free Float
52,171,000
Market Cap
$2.08 billion
Optionable
Optionable
Beta
1.07

Social Links

Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

This page (NASDAQ:NUVA) was last updated on 8/30/2025 by MarketBeat.com Staff
From Our Partners